Last $0.40 USD
Change Today 0.00 / 0.00%
Volume 0.0
UNISZ On Other Exchanges
As of 8:10 PM 09/11/14 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNISZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $0.80
52 Week Low
09/5/14 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UNILIFE CORP-CDI (UNISZ)

Related News

No related news articles were found.

unilife corp-cdi (UNISZ) Related Businessweek News

View More BusinessWeek News

unilife corp-cdi (UNISZ) Details

Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, which combines universal luer connectivity with automatic, user-controlled needle retraction. It also provides ReadyToGo platform of wearable injectors designed for pre-filled, disposable devices that can be worn by a patient over periods during the subcutaneous injection of therapies; LISA smart reusable auto-injector; and RITA disposable auto-injector, an ergonomic single-use product. In addition, the company offers drug reconstitution delivery systems, including AutoMix Presto, an automatic reconstitution for single-step mixing and injection; EZMix Genesis, a ventless one-step reconstitution and automatic user-controlled retraction; EZMix Engage, a one step reconstitution to attach and retract a needle; and EZMix Prodigy, a single-barrel reconstitution system with a pre-fillable syringe. Further, it provides ocular delivery systems comprising Ocu-ject for the delivery of microliter sized doses to the eye; Ocu-mix, a dual-chamber syringe platform to reconstitute or mix, and deliver various therapies into the eye with a single injection; and Depot-ject, which places a drug depot into the eye. Additionally, the company offers Micro-ject to optimize the delivery of therapies with microliter doses that are unsuited to conventional device technologies. It serves pharmaceutical and biotechnology companies. The company was founded in 2002 and is headquartered in York, Pennsylvania.

209 Employees
Last Reported Date: 09/15/14
Founded in 2002

unilife corp-cdi (UNISZ) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: $630.0K
President and Chief Operating Officer
Total Annual Compensation: $511.5K
Vice President of Corporate Quality & Regulat...
Total Annual Compensation: $266.8K
Compensation as of Fiscal Year 2013.

unilife corp-cdi (UNISZ) Key Developments

Unilife Corporation Auditor Raises 'Going Concern' Doubt

Unilife Corporation filed its 10-K on Sep 15, 2014 for the period ending Jun 30, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Unilife Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Unilife Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported revenue of $6,546,000 against $667,000 reported in the same period a year ago. Operating loss was $14,374,000 against $21,641,000 reported last year. Net loss was $15,263,000 or $0.15 per basic and diluted share against $21,977,000 or $0.25 per basic and diluted share reported last year. Adjusted net loss was $11,719,000 or $0.12 per basic and diluted share against $9,864,000 or $0.11 per basic and diluted share reported. For the year, the company reported adjusted net loss was $38,772,000 or $0.40 per basic and diluted share against $38,032,000 or $0.47 per basic and diluted share reported in the same period a year ago. Net operating cash flow loss improved 20% from the year before despite a significant increase in R&D investment in response to growing customer demand. During fiscal year 2015, the company look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, the company expects to increase capital expenditures in response to growing customer demand while moderating investments in R&D and keeping SG&A largely stable. Furthermore, the company expects to narrow its operating income loss and operating cash flow loss at an attractive trend during fiscal year 2015.

Unilife Corporation to Report Q4, 2014 Results on Sep 09, 2014

Unilife Corporation announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Sep 09, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNISZ:US $0.40 USD 0.00

UNISZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.60 USD -0.21
West Pharmaceutical Services Inc $44.05 USD -0.71
Ypsomed Holding AG SFr.84.75 CHF -0.45
View Industry Companies

Industry Analysis


Industry Average

Valuation UNISZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.4x
Price/Book 227.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at